HS-543 induces apoptosis of imatinib-resistant chronic myelogenous leukemia with T315I mutation

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1507-1518

  Kim, Soo Jung ^a   Jung, Kyung Hee ^a   Yan, Hong Hua ^a   Son, Mi Kwon ^a   Fang, Zhenghuan ^a   Ryu, Ye Lim ^a   Lee, Hyunseung ^a   Lim, Joo Han ^a   Suh, Jun Kyu ^b   Kim, JinHee ^c,d   Lee, Soyoung ^c,d   Hong, Sungwoo ^c,d   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b National Research Center for Sexual Medicine College of Medicine   (South Korea)

^c Institute for Basic Science   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Bcr Abl; Chronic myeloid leukemia; HS 543; T315I

Indexed keywords

1 [6 (2 METHOXYPHENYL)BENZO[D]THIAZOL 2 YL] 3 [2 (4 METHYLPIPERAZIN 1 YL)ETHYL]UREA; BCR ABL PROTEIN; CASPASE 3; CYCLINE; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR-ABL1 FUSION PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; G1 PHASE CELL CYCLE CHECKPOINT; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMICAL STRUCTURE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MUTATION; PIPERAZINES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922741784     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2837     Document Type: Article

References (35)

1. Melo JV and Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7(6):441-453.
2. Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M and Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or-resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011; 17(10):3219-3232.
3. Lu Z, Jin Y, Qiu L, Lai Y and Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 2010; 290(2):182-191.
4. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA and Blagosklonny MV. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl-and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther. 2005; 4(4):484-490.
5. Martinelli G, Iacobucci I, Soverini S, Palandri F, Castagnetti F, Rosti G and Baccarani M. Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. Biologics. 2007; 1(2):121-127.
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-880.
7. Blagosklonny MV. STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia. 2002; 16(4):570-572.
8. Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, Hong S. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant. J Med Chem. 2013; 56(9):3531-3545.
9. Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D and Zhu X. Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des. 2007; 70(3):171-181.
10. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Bellew RK and Olson AJ. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J Comput Chem. 1998; 19(14):1639-1662.
11. Kaufmann SH and Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001; 11(12):526-534.
12. Lim YP, Diong LS, Qi R, Druker BJ and Epstein RJ. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther. 2003; 2(12):1369-1377.
13. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY and Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A. 2006; 103(45):16870-16875.
14. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2(5):561-566.
15. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB and Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998; 4(7):1661-1672.
16. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354(24):2531-2541.
17. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J and Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer. 2007; 6:67.
18. Morinaga K, Yamauchi T, Kimura S, Maekawa T and Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCRABL gene amplification. Int J Cancer. 2008; 122(11):2621-2627.
19. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, Barbry P, Deckert M, Cassuto JP, Mari B and Auberger P. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther. 2009; 8(7):1924-1933.
20. Beyazit Y, Kekilli M and Haznedaroglu IC. Secondgeneration BCR-ABL kinase inhibitors in CML. N Engl J Med. 2010; 363(17):1673-1675.
21. Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR and Amarante-Mendes GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ. 2003; 10(5):592-598.
22. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE and Skorski T. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 2002; 21(21):5766-5774.
23. Benekli M, Baer MR, Baumann H and Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003; 101(8):2940-2954.
24. Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK, Gonzalez-Gomez I, Groffen J and Heisterkamp N. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res. 2001; 61(4):1398-1405.
25. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV and Griffin JD. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996; 12(4):839-846.
26. Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M and Goolsby CL. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry A. 2003; 54(2):75-88.
27. Kantrow SP and Piantadosi CA. Release of cytochrome c from liver mitochondria during permeability transition. Biochem Biophys Res Commun. 1997; 232(3):669-671.
28. Kuznetsov AV, Troppmair J, Sucher R, Hermann M, Saks V and Margreiter R. Mitochondrial subpopulations and heterogeneity revealed by confocal imaging: possible physiological role? Biochim Biophys Acta. 2006; 1757(5-6):686-691.
29. Lindsay J, Esposti MD, Gilmore AP. Bcl-2 proteins and mitochondria-specificity in membrane targeting for death. Biochim Biophys Acta. 2011; 1813(4):532-539.
30. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010; 430(2):199-205.
31. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON and Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 1998; 16(11):1383-1390.
32. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F and Fernandez-Luna JL. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000; 191(6):977-984.
33. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011; 117(12):3421-3429.
34. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011; 117(12):3409-3420.
35. Hoover RR, Gerlach MJ, Koh EY and Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene. 2001; 20(41):5826-5835.